Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorInvero Pharma, Inc.

About this trial

XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management \[TTM\]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).

Eligibility criteria

Qualifiers

Age at least 18 years but less than or equal to 80 years

Presumed cardiac cause of arrest

Sustained (>20 minutes) spontaneous circulation upon arrival in the emergency department

No response to verbal commands on arrival to emergency department and prior to randomization (Glasgow Coma Scale score of <8)

Disqualifiers

Written do not attempt resuscitation reported to providers before randomization

Traumatic etiology of arrest, defined as concomitant blunt, penetrating, or burn-related injury, or uncontrolled bleeding or exsanguination

Suspected or known stroke or intracranial hemorrhage

Unwitnessed cardiac arrest

Trial design

Treatments tested in this trial

  • Xenon

Treatment groups

1,436 Participants
are divided into 2 treatment groups

Sponsors and collaborators